Alternatively, both malignancies possibly evolved from a common precursor defined by a predisposition mutation with divergent evolution into MPN through acquisition of the <i>JAK2</i> V617F and AML through acquisition of different mutations. This evidence concerns the gene JAK2 and myeloproliferative disorder.